September 2025 in “Biology of Sex Differences” Females have a higher lifetime risk of alopecia areata than males.
September 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
Thymoma with alopecia areata may be linked to abnormal immune cells.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
July 2025 in “Frontiers in Medicine” Topical immunotherapy can help with severe hair loss, but results vary and need personalized, long-term treatment.
July 2025 in “Preprints.org” Specific miRNA profiles can help diagnose and treat alopecia areata.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
June 2025 in “Preprints.org” Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
Exosome therapy successfully regrew and restored natural hair color in a man with stress-related hair loss.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
April 2025 in “Pharmaceutics” Oil A formulation with Baricitinib shows promise for treating alopecia areata by promoting hair growth.
February 2025 in “International Journal of Molecular Sciences” RIPK1 inhibitors may help prevent alopecia areata by reducing immune cell activity.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
January 2025 in “Lasers in Medical Science” CO2 fractional laser treatment helped regrow hair in a 13-year-old with alopecia areata.
January 2025 in “Journal of Personalized Medicine” People with Alopecia Areata are more likely to have prediabetes and obesity.
December 2024 in “Journal of Clinical Medicine” Minoxidil shows promise for alopecia areata, but more research is needed before it can be recommended as a primary treatment.
November 2024 in “Journal of Cutaneous and Aesthetic Surgery” Combining platelet-rich plasma and minoxidil can effectively regrow hair in severe alopecia areata cases.
October 2024 in “The Journal of Dermatology” Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.
October 2024 in “Frontiers in Immunology” Pertussis toxin may contribute to hair loss in alopecia areata.
August 2024 in “International Journal of Molecular Sciences” Mesenchymal Stem Cell therapy shows promise for treating hair loss in Alopecia Areata.
July 2024 in “Dermatology and Therapy” Darker hair colors may increase the risk of alopecia areata, while lighter hair colors may decrease it.
June 2024 in “Military Medicine” Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
April 2024 in “International journal of molecular sciences” Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.
Betamethasone dipropionate lotion is more effective than minoxidil solution for treating Alopecia Areata.
March 2024 in “Nutrients” Alopecia Areata is linked to specific gut bacteria and metabolites, indicating a complex gut microbiome.
March 2024 in “Skin research and technology” High CRP levels could indicate vitamin D deficiency in people with alopecia areata.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
January 2024 in “JEADV clinical practice” Patients were highly satisfied with shared medical appointments for hair loss treatment.